Rare but serious side effects of Polivy
What exactly qualifies as rare with Polivy?
Clinical trials and post-marketing reports show that severe events occur in less than 5 % of patients, yet they can be life-threatening and require immediate medical attention.
Can Polivy cause serious nerve damage?
Peripheral neuropathy is the most common serious neurologic problem; it may start with tingling or numbness and progress to pain, muscle weakness, or difficulty walking. In some patients the damage is only partly reversible after treatment ends.
What blood-related problems can appear?
Low counts of neutrophils, platelets, and red blood cells can lead to severe infections, bleeding, or profound anemia. Febrile neutropenia requiring hospitalization occurs in roughly 1–3 % of patients.
Is tumor lysis syndrome a risk?
Rapid breakdown of cancer cells can release potassium, phosphate, and uric acid into the blood, producing kidney injury or dangerous heart-rhythm changes. Patients with large tumor burdens or high white-cell counts are at highest risk and are usually given preventive hydration and uric-acid-lowering drugs.
Can the drug trigger serious infections?
Reactivation of hepatitis B, progressive multifocal leukoencephalopathy, and opportunistic infections such as Pneumocystis jirovecii pneumonia have all been reported. Some cases have been fatal, prompting recommendations for antiviral prophylaxis and close viral-load monitoring.
How does liver toxicity present?
Elevated liver enzymes, jaundice, and, in rare instances, hepatic failure can occur. Regular blood tests are required to catch rising transaminases before they become clinically significant.
What infusion reactions should patients watch for?
Fever, chills, low blood pressure, and breathing difficulty can appear during or shortly after the infusion. Severe reactions may necessitate stopping the drug and giving steroids or antihistamines.
When do these side effects typically show up?
Most serious events occur during the first two to three treatment cycles, but late-onset neuropathy and infections have been recorded months after the final dose.
Are there ways to reduce the chance of these complications?
Dose reductions, growth-factor support, prophylactic antimicrobials, and prompt laboratory monitoring are standard strategies used to keep risks manageable while preserving treatment benefit.